Scientists Identify New Drug Target to Combat Antibiotic-Resistant E. col
Published: 18 Mar 2026
Author: Precedence Research
Researchers at the University of Alberta have identified a promising new drug target that could help combat antibiotic-resistant Escherichia coli infections. The discovery provides a potential pathway for developing new treatments against bacterial strains that are becoming increasingly difficult to treat with existing antibiotics.
Rising Threat of Antibiotic-Resistant Bacteria
Antibiotic resistance is a growing global health concern, with harmful E. coli strains contributing significantly to severe infections and deaths worldwide. These bacteria are responsible for many illnesses, including urinary tract infections and bloodstream infections, and the rising resistance to antibiotics has made treatment increasingly challenging.
According to Towards Healthcare, the Antimicrobial Urinary Catheters Market is projected to grow significantly from USD 1.35 billion in 2026 to approximately USD 2.8 billion by 2035, representing a CAGR of 8.48%. Antimicrobial urinary catheters are linked to biofilm formation, which protects bacteria from the immune system and contributes to chronic infection.
Discovery of a Key Bacterial Weak Point
The research team discovered that a bacterial enzyme known as GlpG, a rhomboid protease, plays a crucial role in helping E. coli maintain structures called type 1 pili. These hair-like appendages allow bacteria to attach to host cells, enabling infection and colonisation. By interfering with GlpG, scientists found that the bacteria struggle to assemble these pili properly.
Without properly formed pili, the bacteria lose their ability to adhere to host tissues and form protective biofilms, significantly reducing their ability to cause disease.
Impact on Biofilm Formation and Infection
Biofilms are clusters of bacteria that attach to surfaces and shield themselves from antibiotics and immune responses. The study showed that disabling or inhibiting GlpG dramatically reduces biofilm formation, making the bacteria more vulnerable and less capable of sustaining infections. This finding is significant because biofilms often play a major role in persistent and recurrent infections.
Research Published in a Leading Scientific Journal
The findings were published in the journal Nature Communications by a team led by scientists including Jimmy Lu and M. Joanne Lemieux. The study provides new insights into how bacterial virulence mechanisms function and how they might be disrupted with targeted therapies.
Toward New Antibiotic Strategies
Instead of killing bacteria directly, targeting virulence factors like GlpG could weaken pathogens and prevent them from establishing infections. This approach may also slow the development of resistance compared with traditional antibiotics.
The researchers believe that GlpG could serve as a promising starting point for designing next-generation drugs aimed at tackling antibiotic-resistant bacterial infections.
A recent report by Towards Healthcare highlights that the Antimicrobial Urinary Catheters Market is experiencing we invest in developing antibacterial countermeasures now, because the drug discovery pipeline does take a long time.